0

Close
 
Upcoming Allied Market Research
2023
Neurovascular Market

Neurovascular Market

by THERAPEUTICS (Endovascular cerebral aneurysm, Intracranial atherosclerotic disease, Chronic ischemic stroke, Acute ischemic stroke) and by DEVICES (Neurovascular liquid embolism, Intracranial stents flow diverting devices, Neurovascular embolic coils, Carotid stents embolic protection devices, Neurovascular thrombectomy devices): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A00025
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Neurovascular Market

Request Now !

Neurovascular disease is a condition caused to nervous tissues vascular structure, neurons and blood vessels that leads to serious brain damages such as stroke, and cerebral hemorrhage. The global market for central nervous system disease was accounted to approximately $78 billion in 2010. Neurovascular disease market is mainly driven by the increase in number of patients suffering from neurological diseases. According to University of California, San Francisco (USCF), there are approximately 600,000 people suffering from stroke, out of which 10% are recovered. Almost 30% patients die due to stroke, and 60% of the patients remain disabled. The cost of care for these 60% patients accounted to approximately $8 billion. Cost of neurological disease treatment is lowering the growth for neurological disease. Companies are conducting clinical trials to commercialized cost effective therapies through mergers and acquisitions.

Medical device manufacturing companies are facing challenges in the form of commercialization in developing countries such as India, China, and Malaysia. However, increase in research on neurovascular therapies, and favorable government policies, would give the necessary push to the neurovascular market. This report gives intelligence about current market trends available and transition of these trends in future. Market intelligence of key patents granted by respective authorities is provided in this report.

The key companies included in this report are Medtronic, Stryker, Covidien (Ev3) , Johnson & Johnson (Micrus), Abbott Laboratories, Bayer AG, Boston Scientific Corporation, Cardiatis, S.A., Chestnut Medical Technologies, Inc., Johnson & Johnson, ITGI Medical Ltd.

KEY BENEFITS

  • Key developmental strategies adopted by top market players engaged in this business, so that companies involved in development of neurovascular device can get competitive intelligence of their competitors
  • Market estimation for therapeutic devices and geographic segment is derived from current market scenario and expected market trends
  • Market attractiveness analysis has been included for various product segments, therapeutics, devices and geographic regions with detailed analysis of factors responsible for rapid growth of the market segments
  • In depth analysis of key market drivers, restraints and opportunities of non-invasive diagnostic market with impact analysis
  • Value chain analysis, Porter’s five force model, top investment pockets (GE9 Cell Matrix) are analyzed and presented in detail in the report so that the decision makers receive clear picture of neurovascular disease treatment market

 Neurovascular Market Report Highlights

Aspects Details
By THERAPEUTICS
  • Endovascular cerebral aneurysm
  • Intracranial atherosclerotic disease
  • Chronic ischemic stroke
  • Acute ischemic stroke
By DEVICES
  • Neurovascular liquid embolism
  • Intracranial stents & flow diverting devices
  • Neurovascular embolic coils
  • Carotid stents & embolic protection devices
  • Neurovascular thrombectomy devices
By GEOGRAPHY
  • North America
  • Europe
  • Asia-Pacific
  • ROW
Key Market Players Academic Institutes, Medical device manufacturing companies, Government and Private research laboratories, Research based pharmaceutical companies
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: NEUROVASCULAR MARKET, BY THERAPEUTICS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapeutics

    • 4.2. Endovascular Cerebral Aneurysm

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Intracranial Atherosclerotic Disease

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Chronic Ischemic Stroke

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Acute Ischemic Stroke

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: NEUROVASCULAR MARKET, BY DEVICES

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Devices

    • 5.2. Neurovascular Liquid Embolism

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Intracranial Stents Flow Diverting Devices

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Neurovascular Embolic Coils

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Carotid Stents Embolic Protection Devices

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Neurovascular Thrombectomy Devices

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: NEUROVASCULAR MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Therapeutics

      • 6.2.3. Market Size and Forecast, By Devices

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Neurovascular Market

        • 6.2.5.1. Market Size and Forecast, By Therapeutics
        • 6.2.5.2. Market Size and Forecast, By Devices

      • 6.2.6. Canada Neurovascular Market

        • 6.2.6.1. Market Size and Forecast, By Therapeutics
        • 6.2.6.2. Market Size and Forecast, By Devices

      • 6.2.7. Mexico Neurovascular Market

        • 6.2.7.1. Market Size and Forecast, By Therapeutics
        • 6.2.7.2. Market Size and Forecast, By Devices

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Therapeutics

      • 6.3.3. Market Size and Forecast, By Devices

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Neurovascular Market

        • 6.3.5.1. Market Size and Forecast, By Therapeutics
        • 6.3.5.2. Market Size and Forecast, By Devices

      • 6.3.6. Germany Neurovascular Market

        • 6.3.6.1. Market Size and Forecast, By Therapeutics
        • 6.3.6.2. Market Size and Forecast, By Devices

      • 6.3.7. Italy Neurovascular Market

        • 6.3.7.1. Market Size and Forecast, By Therapeutics
        • 6.3.7.2. Market Size and Forecast, By Devices

      • 6.3.8. Spain Neurovascular Market

        • 6.3.8.1. Market Size and Forecast, By Therapeutics
        • 6.3.8.2. Market Size and Forecast, By Devices

      • 6.3.9. UK Neurovascular Market

        • 6.3.9.1. Market Size and Forecast, By Therapeutics
        • 6.3.9.2. Market Size and Forecast, By Devices

      • 6.3.10. Russia Neurovascular Market

        • 6.3.10.1. Market Size and Forecast, By Therapeutics
        • 6.3.10.2. Market Size and Forecast, By Devices

      • 6.3.11. Rest Of Europe Neurovascular Market

        • 6.3.11.1. Market Size and Forecast, By Therapeutics
        • 6.3.11.2. Market Size and Forecast, By Devices

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Therapeutics

      • 6.4.3. Market Size and Forecast, By Devices

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Neurovascular Market

        • 6.4.5.1. Market Size and Forecast, By Therapeutics
        • 6.4.5.2. Market Size and Forecast, By Devices

      • 6.4.6. Japan Neurovascular Market

        • 6.4.6.1. Market Size and Forecast, By Therapeutics
        • 6.4.6.2. Market Size and Forecast, By Devices

      • 6.4.7. India Neurovascular Market

        • 6.4.7.1. Market Size and Forecast, By Therapeutics
        • 6.4.7.2. Market Size and Forecast, By Devices

      • 6.4.8. South Korea Neurovascular Market

        • 6.4.8.1. Market Size and Forecast, By Therapeutics
        • 6.4.8.2. Market Size and Forecast, By Devices

      • 6.4.9. Australia Neurovascular Market

        • 6.4.9.1. Market Size and Forecast, By Therapeutics
        • 6.4.9.2. Market Size and Forecast, By Devices

      • 6.4.10. Thailand Neurovascular Market

        • 6.4.10.1. Market Size and Forecast, By Therapeutics
        • 6.4.10.2. Market Size and Forecast, By Devices

      • 6.4.11. Malaysia Neurovascular Market

        • 6.4.11.1. Market Size and Forecast, By Therapeutics
        • 6.4.11.2. Market Size and Forecast, By Devices

      • 6.4.12. Indonesia Neurovascular Market

        • 6.4.12.1. Market Size and Forecast, By Therapeutics
        • 6.4.12.2. Market Size and Forecast, By Devices

      • 6.4.13. Rest of Asia Pacific Neurovascular Market

        • 6.4.13.1. Market Size and Forecast, By Therapeutics
        • 6.4.13.2. Market Size and Forecast, By Devices

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Therapeutics

      • 6.5.3. Market Size and Forecast, By Devices

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Neurovascular Market

        • 6.5.5.1. Market Size and Forecast, By Therapeutics
        • 6.5.5.2. Market Size and Forecast, By Devices

      • 6.5.6. South Africa Neurovascular Market

        • 6.5.6.1. Market Size and Forecast, By Therapeutics
        • 6.5.6.2. Market Size and Forecast, By Devices

      • 6.5.7. Saudi Arabia Neurovascular Market

        • 6.5.7.1. Market Size and Forecast, By Therapeutics
        • 6.5.7.2. Market Size and Forecast, By Devices

      • 6.5.8. UAE Neurovascular Market

        • 6.5.8.1. Market Size and Forecast, By Therapeutics
        • 6.5.8.2. Market Size and Forecast, By Devices

      • 6.5.9. Argentina Neurovascular Market

        • 6.5.9.1. Market Size and Forecast, By Therapeutics
        • 6.5.9.2. Market Size and Forecast, By Devices

      • 6.5.10. Rest of LAMEA Neurovascular Market

        • 6.5.10.1. Market Size and Forecast, By Therapeutics
        • 6.5.10.2. Market Size and Forecast, By Devices

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Medical Device Manufacturing Companies

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Research Based Pharmaceutical Companies

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Academic Institutes

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Government And Private Research Laboratories

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NEUROVASCULAR MARKET, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL NEUROVASCULAR MARKET FOR ENDOVASCULAR CEREBRAL ANEURYSM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL NEUROVASCULAR MARKET FOR INTRACRANIAL ATHEROSCLEROTIC DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR MARKET FOR CHRONIC ISCHEMIC STROKE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR MARKET FOR ACUTE ISCHEMIC STROKE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR MARKET, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR MARKET FOR NEUROVASCULAR LIQUID EMBOLISM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR MARKET FOR INTRACRANIAL STENTS FLOW DIVERTING DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR MARKET FOR NEUROVASCULAR EMBOLIC COILS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR MARKET FOR CAROTID STENTS EMBOLIC PROTECTION DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR MARKET FOR NEUROVASCULAR THROMBECTOMY DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA NEUROVASCULAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 16. U.S. NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 17. U.S. NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 18. CANADA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 19. CANADA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 20. MEXICO NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 21. MEXICO NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE NEUROVASCULAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 28. GERMANY NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 29. ITALY NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 30. ITALY NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 33. UK NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 34. UK NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 35. RUSSIA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 36. RUSSIA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 38. REST OF EUROPE NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC NEUROVASCULAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 42. CHINA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 43. CHINA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 44. JAPAN NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 45. JAPAN NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 46. INDIA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 47. INDIA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 48. SOUTH KOREA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 49. SOUTH KOREA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 50. AUSTRALIA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 51. AUSTRALIA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 52. THAILAND NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 53. THAILAND NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 54. MALAYSIA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 55. MALAYSIA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 56. INDONESIA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 57. INDONESIA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA NEUROVASCULAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 62. LAMEA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 63. BRAZIL NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 64. BRAZIL NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH AFRICA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH AFRICA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 67. SAUDI ARABIA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 68. SAUDI ARABIA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 69. UAE NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 70. UAE NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 71. ARGENTINA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 72. ARGENTINA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 73. REST OF LAMEA NEUROVASCULAR, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 74. REST OF LAMEA NEUROVASCULAR, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 75. MEDICAL DEVICE MANUFACTURING COMPANIES: KEY EXECUTIVES
  • TABLE 76. MEDICAL DEVICE MANUFACTURING COMPANIES: COMPANY SNAPSHOT
  • TABLE 77. MEDICAL DEVICE MANUFACTURING COMPANIES: OPERATING SEGMENTS
  • TABLE 78. MEDICAL DEVICE MANUFACTURING COMPANIES: PRODUCT PORTFOLIO
  • TABLE 79. MEDICAL DEVICE MANUFACTURING COMPANIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. RESEARCH BASED PHARMACEUTICAL COMPANIES: KEY EXECUTIVES
  • TABLE 81. RESEARCH BASED PHARMACEUTICAL COMPANIES: COMPANY SNAPSHOT
  • TABLE 82. RESEARCH BASED PHARMACEUTICAL COMPANIES: OPERATING SEGMENTS
  • TABLE 83. RESEARCH BASED PHARMACEUTICAL COMPANIES: PRODUCT PORTFOLIO
  • TABLE 84. RESEARCH BASED PHARMACEUTICAL COMPANIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. ACADEMIC INSTITUTES: KEY EXECUTIVES
  • TABLE 86. ACADEMIC INSTITUTES: COMPANY SNAPSHOT
  • TABLE 87. ACADEMIC INSTITUTES: OPERATING SEGMENTS
  • TABLE 88. ACADEMIC INSTITUTES: PRODUCT PORTFOLIO
  • TABLE 89. ACADEMIC INSTITUTES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: KEY EXECUTIVES
  • TABLE 91. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: COMPANY SNAPSHOT
  • TABLE 92. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: OPERATING SEGMENTS
  • TABLE 93. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 94. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NEUROVASCULAR MARKET
  • FIGURE 3. SEGMENTATION NEUROVASCULAR MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NEUROVASCULAR MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNEUROVASCULAR MARKET
  • FIGURE 11. NEUROVASCULAR MARKET SEGMENTATION, BY BY THERAPEUTICS
  • FIGURE 12. NEUROVASCULAR MARKET FOR ENDOVASCULAR CEREBRAL ANEURYSM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NEUROVASCULAR MARKET FOR INTRACRANIAL ATHEROSCLEROTIC DISEASE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. NEUROVASCULAR MARKET FOR CHRONIC ISCHEMIC STROKE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. NEUROVASCULAR MARKET FOR ACUTE ISCHEMIC STROKE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. NEUROVASCULAR MARKET SEGMENTATION, BY BY DEVICES
  • FIGURE 17. NEUROVASCULAR MARKET FOR NEUROVASCULAR LIQUID EMBOLISM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. NEUROVASCULAR MARKET FOR INTRACRANIAL STENTS FLOW DIVERTING DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. NEUROVASCULAR MARKET FOR NEUROVASCULAR EMBOLIC COILS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. NEUROVASCULAR MARKET FOR CAROTID STENTS EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. NEUROVASCULAR MARKET FOR NEUROVASCULAR THROMBECTOMY DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: NEUROVASCULAR MARKET
  • FIGURE 28. Top player positioning, 2022
  • FIGURE 29. MEDICAL DEVICE MANUFACTURING COMPANIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. MEDICAL DEVICE MANUFACTURING COMPANIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. MEDICAL DEVICE MANUFACTURING COMPANIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. RESEARCH BASED PHARMACEUTICAL COMPANIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. RESEARCH BASED PHARMACEUTICAL COMPANIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. RESEARCH BASED PHARMACEUTICAL COMPANIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. ACADEMIC INSTITUTES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. ACADEMIC INSTITUTES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. ACADEMIC INSTITUTES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Neurovascular Market

Start reading.
This Report and over 66,965+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers